王慧君 / Heidi Wang
Summary
Dr. Heidi Wang is an experienced global drug development and regulatory expert with more than 30 years of Pharmaceutical Industry and Biotech experience. With expertise in Oncology, Virology, Immunology, and other therapeutic areas, Heidi led and contributed to shaping strategy and delivering approvals for Bristol Myers Squibb Company (BMS) and now, for OBI and OBIGEN. Importantly, Heidi’s positive leadership style and inclusive mindset helped to transform company’s culture and processes to optimize their portfolio acceleration and to bring people together. Leveraging her strengths in problem solving, risk mitigation, and asking the right questions, coupled with a deep expertise in drug development, Heidi is now guiding OBI. OBIGEN, and as a Board member of a Taiwan-based company and her alma mater, Fu-Jen University. She volunteers as an advisor and mentor to individuals and multiple organizations in the US, Europe, and Taiwan.
Work, Passion and Leadership
During her ~30 years tenure at BMS, Dr. Heidi Wang changed her roles 10 times and was promoted 8 times, each with growing responsibilities. She started her career as a virologist and successfully brought 10 New Molecular Entities and numerous supplemental indication approvals for medicines in HIV, Hepatitis B, and Hepatitis C, Immunology, Cardiovascular, and Oncology to the US and international markets, including China. Her final job at BMS was the Vice President and Head of Global Regulatory Sciences in Oncology where she led the teams to 17 regulatory approvals (including 2 new molecules) worldwide in 3 years. With Heidi’s coaching and providing strategic guidance to teams, some US approvals took only 39 and 45 days, respectively. These best practices were shared and expanded to the entire company at BMS. In the CEO role at OBI Pharma, Heidi has changed the company’s siloed culture, encouraged an “inclusive” mindset, reshaped the portfolio with a laser focus on Antibody-Drug-Conjugate (ADC) assets, and drove the development of unique ADC platform technologies that are likely “best-in-class”. Heidi’s twin passions are to bring new medicines to patients around the globe and to give back. Hence, she shaped both companies’ global drug development strategy and processes, to convert colleagues’ mindset to think globally from early stages of clinical development, to enable acceleration in submissions and approvals, and to ensure success in reimbursement and commercial areas. She volunteers as a mentor and advisor to colleagues and organizations in the US and Taiwan to give back to the community. Overcoming challenges and remaining calm under pressure are Heidi’s core strengths. She thinks innovatively and asks the right questions. These attributes are why Heidi is successful at identifying and mitigating risks and enabling BMS and OBI to grow and accelerate their respective portfolios.
Education
Heidi received her B.S. degree from Fu-Jen University in Taiwan. After receiving her M.S. and Ph.D. degrees in Molecular Biology and Virology from University of Notre Dame in Notre Dame, IN, USA, Heidi had postdoctoral training in Cancer Biology at the Cold Spring Harbor Laboratory in New York, USA. In addition to English, she is a native speaker of Chinese (mandarin).
Board
Heidi was appointed as the Chairman of the OBIGEN Board in March, 2025. She was elected as a Board member to OBI Pharma, Amaran, and at her alma mater, Fu-Jen University US Foundation. In this Fu-Jen Foundation, Heidi was assigned to the Fundraising committee. Heidi was honored as an outstanding alumnus at Fu-Jen University in 2023 and had received multiple honors in recent years.